Publications by authors named "G A Koenig"

Objectives: There is a paucity of data on the use of protamine after PCI. The purpose of this study was to assess the incidence of thrombotic complications of protamine after high-risk PCI.

Methods: The authors conducted a retrospective analysis of 168 patients.

View Article and Find Full Text PDF

Background: Novel motion-compensated treatment techniques on the MR-linac can address adverse intra-fraction motion effects. These techniques involve beam gating or intra-fraction adaptations of the treatment plan based on real-time magnetic resonance imaging (MRI) performed during treatment. For quality assurance (QA) of these workflows, a multi-purpose motion platform is desirable.

View Article and Find Full Text PDF

The ribosome maturation factor Rea1 (or Midasin) catalyses the removal of assembly factors from large ribosomal subunit precursors and promotes their export from the nucleus to the cytosol. Rea1 consists of nearly 5000 amino-acid residues and belongs to the AAA+ protein family. It consists of a ring of six AAA+ domains from which the ≈1700 amino-acid residue linker emerges that is subdivided into stem, middle and top domains.

View Article and Find Full Text PDF

Left atrial veno-arterial extracorporeal membrane oxygenation (LAVA-ECMO) in cardiogenic shock (CS) is a novel mechanical cardiocirculatory support strategy that provides robust cardiocirculatory support and simultaneous left and right atrial venting by way of a multifenestrated transeptal catheter. We performed a single-center retrospective analysis of all patients aged ≥18 years with CS who underwent LAVA-ECMO at a quaternary care institution from 2018 to 2023. Clinical outcomes and prehemodynamics and posthemodynamics were evaluated.

View Article and Find Full Text PDF
Article Synopsis
  • Mechanical circulatory support with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has improved treatment for cardiogenic shock, but neurological complications, especially strokes, are a major concern and can affect patient outcomes.
  • A study at a quaternary center analyzed 244 patients on VA-ECMO from 2018-2022, finding that 14.7% developed a stroke, with ischemic and hemorrhagic strokes occurring almost equally.
  • Key risk factors for stroke included the use of P2Y antagonists, limb ischemia, and the need for blood transfusions, while there was no significant link between stroke incidence and overall mortality or the length of VA-EC
View Article and Find Full Text PDF